Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice. .
【中文题目：ALK融合阳性非小细胞肺癌 新辅助靶向治疗的进展】 【中文摘要：肺癌仍然是世界范围内最常见的癌症和癌症相关死亡的主要原因，其中间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）融合突变所占的比例为4%-9%。近年来，越来越多的临床证据表明ALK抑制剂与手术治疗相结合的治疗模式在可切除的早期与局部晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者中存在着较大的临床应用潜力。本综述旨在总结ALK融合阳性NSCLC新辅助靶向治疗的研究进展，并分析其在临床实践中的优势与挑战。 】 【中文关键词：肺肿瘤；ALK融合阳性；新辅助治疗；靶向治疗】.
Keywords: ALK-positive; Lung neoplasms; Neoadjuvant therapy; Targeted therapy.